COMPANY PROFILE

Cellestia Biotech

Explore full profile

A bio-pharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway

Basel, SwitzerlandFounded 2014Biotech & Life Sciences

Valuation $50–100M Last recorded · 2019

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Cellestia Biotech

Cellestia Biotech is a pioneering startup operating in the biotechnology industry, specifically focusing on the development of innovative therapeutics for autoimmune diseases and multi-drug resistant cancers. The company's mission is to improve the quality of life for patients who currently have limited or no treatment options.

Read full description

Cellestia's business model revolves around the research, development, and commercialization of groundbreaking novel therapies. They are relentless in their pursuit of new modes of action that can potentially cure previously incurable diseases. Their dedication to patients is uncompromising, always putting the needs of the patients first in their quest for therapeutic solutions.

The company's target market is primarily patients suffering from autoimmune diseases and multi-drug resistant cancers. These are individuals who are in desperate need of effective treatments and therapies. Cellestia aims to fill this gap by providing them with safe and effective therapeutic solutions.

Cellestia generates revenue through the development and commercialization of their innovative therapies. Once a therapy has been developed and approved for use, it can be sold to healthcare providers and directly to patients. The company's potential for revenue growth is significant given the high demand for effective treatments for autoimmune diseases and multi-drug resistant cancers.

In conclusion, Cellestia Biotech is a dedicated and innovative player in the biotechnology industry. Their relentless pursuit of groundbreaking therapies for autoimmune diseases and multi-drug resistant cancers sets them apart in the market. Their commitment to improving the quality of life for patients is commendable and is a driving force behind their research and development efforts.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Basel, Switzerland
Employees: 6
Open positions: None listed
Dealroom signal: 61.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biochemical, Spinout, Sustainable Development Goals, Biotech and Pharma, Horizon Europe, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SUPPORT PROGRAM✓Other financing	Jun 2024	$0	—	Swissnex	—
SUPPORT PROGRAM✓Other financing	Jan 2024	$0	—	Swissnex	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Cellestia Biotech website traffic

Latest recorded traffic for Cellestia Biotech is 1.4K monthly website visits, up 218.2% over the last three months. Cellestia Biotech's team declined 25% over the past year.

Latest monthly visits1.4K 3-month web change+218.2% 1-year team growth-25%

Monthly website visitsJun 2017–Sep 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NUNucleixDeveloping cancer diagnostic panels based on epigenetic bio markers	Rehovot, Israel	Operational	70	$83M	$275M
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
EBEvaxion BiotechPioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence	Hørsholm, Denmark	Operational
TTTOLREMO therapeuticsFocused on the discovery and development of small molecules to prevent resistance in cancer therapy	Basel, Switzerland	Operational
IOiOncturaOncology therapies countering immunosuppression in tumors	Geneva, Switzerland	Operational
LBLeukos BiotechNew treatments for Acute Myeloid Leukaemia and other haematological malignancies	Barcelona, Spain	Operational
IPIndex PharmaceuticalsDeveloping drugs to treat inflammatory bowel disease that can help patients return to a normal life	Solna kommun, Sweden	Operational